Healthcare / Medical Instruments & SuppliesTokyo
$1911.00
+24.00 (+1.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.9B · quality 64.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$58.5B
P/E
14.6x
↓EV/EBITDA
9.5x
↓ROE
15.9%
↑Gross Margin
76.7%
↑Debt/Equity
0.73
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.8%
FCF CAGR
+12.8%
FCF margin
5.9%
FCF / Net income
0.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $50.15B · net income $4.12B · FCF $2.95B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $50.15B | $50.15B | $44.84B | $39.88B | $35.89B |
| Net Income | $4.12B | $4.12B | $3.52B | $2.56B | $1.27B |
| EBITDA | $7.11B | $7.11B | $5.66B | $4.18B | $3.12B |
| EPS | — | — | 145.66 | 119.61 | 43.23 |
| Gross Margin | 76.7% | 76.7% | 75.2% | 72.7% | 74.5% |
| Operating Margin | 11.9% | 11.9% | 11.2% | 8.8% | 7.9% |
| Net Margin | 8.2% | 8.2% | 7.8% | 6.4% | 3.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.73 | 0.73 | 0.14 | 1.14 | 1.75 |
| Current Ratio | 1.04 | 1.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.95B | $2.95B | $4.88B | $1.21B | $2.05B |
| Returns | |||||
| ROE | 15.9% | 15.9% | 15.2% | 40.2% | 30.8% |
| Valuation | |||||
| P/E | 14.59 | 14.59 | 17.77 | — | — |
| EV/EBITDA | 9.47 | 9.47 | 8.08 | — | — |
| P/B | 2.25 | 2.25 | 2.71 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 11.8% | 11.8% | 12.5% | 11.1% | — |
| EPS Growth | — | — | 21.8% | 176.7% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.7%
Start / end P/E
n/dx → n/dx
EPS bridge
145.66 → n/d
Residual
-12.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.